Literature DB >> 27107572

Inhibition of pathological angiogenesis of Chinese medicine against liver fibrosis.

Ping Liu1.   

Abstract

Pathological angiogenesis of liver which includes liver sinusoidal capillarization due to lose of fenestraes of liver sinusoidal endothelial cells (LSECs) and formation of new vascular, is a crucial mechanism responsible for origination and development of liver fifibrosis and closely involves in the development of cirrhosis and hepatic cancer. Anti-neovascularization medicine such as sorafenib can decrease portosystemic shunts, improve splanchnic hyperdynamic circulation, lower portal hypertension, while it can not be applied in clinic due to its serious toxic and side reactions. Chinese herbal formula can effectively inhibit pathological angiogenesis of liver, improve microcirculation of liver, and decrease the probability of gastrointestinal hemorrhage in cirrhotic patients. Different Chinese herbal formula are of different characteristics on inhibiting pathological angiogenesis in liver fifibrosis, which partly explains synergistic effect of different compatibility of Chinese materia medica and opens up good vista for Chinese medicine against liver fifibrosis through inhibiting angiogenesis.

Entities:  

Keywords:  Chinese medicine; liver fifibrosis; pathological angiogenesis

Mesh:

Substances:

Year:  2016        PMID: 27107572     DOI: 10.1007/s11655-016-2468-3

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  17 in total

1.  Xuefuzhuyu decoction inhibition of angiogenesis attenuates liver fibrosis induced by CCl₄ in mice.

Authors:  Ya-Ning Zhou; Ming-Yu Sun; Yong-Ping Mu; Tao Yang; Bing-Bing Ning; Shuang Ren; Jia-Mei Chen; Ping Liu
Journal:  J Ethnopharmacol       Date:  2014-03-15       Impact factor: 4.360

2.  Arsenic stimulates sinusoidal endothelial cell capillarization and vessel remodeling in mouse liver.

Authors:  Adam C Straub; Donna B Stolz; Mark A Ross; Araceli Hernández-Zavala; Nicole V Soucy; Linda R Klei; Aaron Barchowsky
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

3.  [Chinese herbal medicine Xiayuxue Decoction inhibits liver angiogenesis in rats with carbon tetrachloride-induced liver fibrosis].

Authors:  Jin-xing Du; Ping Liu; Ming-yu Sun; Qing Tao; Li-jun Zhang; Gao-feng Chen; Yi-yang Hu; Cheng-hai Liu; Lie-ming Xu
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2011-08

4.  Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.

Authors:  Han-Chieh Lin; Yi-Tsau Huang; Ying-Ying Yang; Pei-Chang Lee; Lih-Hwa Hwang; Wei-Ping Lee; Ying-Ju Kuo; Kuei-Chuan Lee; Yun-Cheng Hsieh; Ren-Shyan Liu
Journal:  J Gastroenterol Hepatol       Date:  2014-05       Impact factor: 4.029

5.  [Intervening and therapeutic effect of cordyceps mycelia extract on liver cirrhosis induced by dimethylnitrosamine in rats].

Authors:  Xian-Bo Wang; Ping Liu; Zhi-Peng Tang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2008-07

6.  Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.

Authors:  Marc Mejias; Ester Garcia-Pras; Carolina Tiani; Rosa Miquel; Jaime Bosch; Mercedes Fernandez
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

7.  Xiayuxue Decoction ([symbols; see text]) attenuates hepatic stellate cell activation and sinusoidal endothelium defenestration in CCl4-induced fibrotic liver of mice.

Authors:  Li-jun Zhang; Ming-yu Sun; Bing-bing Ning; Wen-meng Zhang; Gao-feng Chen; Yong-ping Mu; Hua Zhang; Jia Liu; Yan-qin Bian; Ping Liu
Journal:  Chin J Integr Med       Date:  2014-06-28       Impact factor: 1.978

8.  Yiguanjian decoction and its ingredients inhibit angiogenesis in carbon tetrachloride-induced cirrhosis mice.

Authors:  Ya-Ning Zhou; Yong-Ping Mu; Wen-Wei Fu; Bing-Bing Ning; Guang-Li Du; Jia-Mei Chen; Ming-Yu Sun; Hua Zhang; Yi-Yang Hu; Cheng-Hai Liu; Lie-Ming Xu; Ping Liu
Journal:  BMC Complement Altern Med       Date:  2015-10-01       Impact factor: 3.659

9.  Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis.

Authors:  Bi-Sen Ding; Zhongwei Cao; Raphael Lis; Daniel J Nolan; Peipei Guo; Michael Simons; Mark E Penfold; Koji Shido; Sina Y Rabbany; Shahin Rafii
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

10.  In the non-cirrhotic stage of nonalcoholic steatohepatitis, angioarchitecture of portal veins and lobular architecture are maintained.

Authors:  Hiroshi Hano; Satoshi Takasaki; Hirohiko Kobayashi; Tomoki Koyama; Tomoe Lu; Keisuke Nagatsuma
Journal:  Virchows Arch       Date:  2013-03-28       Impact factor: 4.064

View more
  4 in total

1.  Levistilide A inhibits angiogenesis in liver fibrosis via vascular endothelial growth factor signaling pathway.

Authors:  Zhi-Min Zhao; Hong-Liang Liu; Xin Sun; Tao Guo; Li Shen; Yan-Yan Tao; Cheng-Hai Liu
Journal:  Exp Biol Med (Maywood)       Date:  2017-03-22

2.  Anti-fibrotic Effects and Mechanism of Shengmai Injection () on Human Hepatic Stellate Cells LX-2.

Authors:  Yi Zhang; Li-Tian Ma; Jie Li; Yu Qiao; Jun-Ye Liu; Jin Wang; Qin-You Ren; Jin-Tao Hu; Jin Zheng
Journal:  Chin J Integr Med       Date:  2018-11-22       Impact factor: 1.978

3.  Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium.

Authors:  Jianxiong Wu; Xietao Ye; Songhong Yang; Huan Yu; Lingyun Zhong; Qianfeng Gong
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

4.  Network Pharmacological Analysis and Experimental Validation of the Mechanisms of Action of Si-Ni-San Against Liver Fibrosis.

Authors:  Siliang Wang; Cheng Tang; Heng Zhao; Peiliang Shen; Chao Lin; Yun Zhu; Dan Han
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.